Abstract: The present invention relates to a container for liquids, a method of filling it and the use of the container according to the invention for holding and storing radioactive substances. The container for a liquid comprises a cavity for holding the liquid, the cavity being bounded by walls (1) at the sides and at the bottom, an opening for filling the cavity with the liquid, a closure for closing off the cavity, the closure having a piercing region for inserting a cannula into the cavity, a bottom casing (20) which surrounds the walls of the cavity in the standing area, a top casing (10) which surrounds the pierceable closure with the exception of the piercing region, and a film (30) which extends from the top casing to the bottom casing and surrounds those areas of the walls of the cavity which are not already surrounded by the top casing or bottom casing.

Abstract: A pharmaceutical preparation comprising at least one complexed alpha-emitting radionuclide and at least one polysaccharide biopolymer.

Abstract: The present invention relates to a method for the generation of 223Ra of pharmaceutically tolerable purity comprising: i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra in a first aqueous solution comprising a first mineral acid; ii) loading said generator mixture onto a DGA separation medium (e.g. resin); iii) eluting said 223Ra from said DGA separation medium using a second mineral acid in a second aqueous solution to give an eluted 223Ra solution; and iv) stripping the DGA separation medium of said 227Ac and 227Th by flowing a third mineral acid in a third aqueous solution through the DGA separation medium in a reversed direction; The invention further relates to high purity radium-223 formed or formable by such a method as well as pharmaceutical compositions comprising such radium-223 of pharmaceutical purity.

Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor. Methods of treatment utilising such complexes and methods of formation of such complexes are provided.

Abstract: The present invention provides a method for the generation of 223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said 223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted 223Ra solution; iv) loading the 223Ra of the first eluted 223Ra solution onto a strong acid cation exchange resin; and v) eluting the 223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.

Abstract: The invention provides a method for the treatment of soft tissue disease in a mammalian subject (preferably a human or canine subject), said method comprising administering to said subject a therapeutically effective quantity of a soft tissue targeting complex of thorium-227 and a complexing agent, wherein said quantity is such that an acceptably non-myelotoxic quantity of radium-223 is generated in vivo by nuclear decay of the administered thorium-227.

Abstract: The present invention relates to a container for liquids, a method of filling it and the use of the container according to the invention for holding and storing radioactive substances. The container for a liquid comprises a cavity for holding the liquid, the cavity being bounded by walls (1) at the sides and at the bottom, an opening for filling the cavity with the liquid, a closure for closing off the cavity, the closure having a piercing region for inserting a cannula into the cavity, a bottom casing (20) which surrounds the walls of the cavity in the standing area, a top casing (10) which surrounds the pierceable closure with the exception of the piercing region, and a film (30) which extends from the top casing to the bottom casing and surrounds those areas of the walls of the cavity which are not already surrounded by the top casing or bottom casing.

Abstract: The present invention provides a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand and the ion of an alpha-emitting thorium radionuclide. The invention additionally provides therapeutic methods employing such complexes, methods of their production and use, and kits and pharmaceutical compositions comprising such complexes.

Abstract: The present invention provides a method for the generation of 223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said 223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted 223Ra solution; iv) loading the 223Ra of the first eluted 223Ra solution onto a strong acid cation exchange resin; and v) eluting the 223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.

Abstract: The present invention relates to a method for the generation of 223Ra of pharmaceutically tolerable purity comprising: i) preparing a generator mixture comprising 227Ac, 227Th and 223Ra in a first aqueous solution comprising a first mineral acid; ii) loading said generator mixture onto a DGA separation medium (e.g. resin); iii) eluting said 223Ra from said DGA separation medium using a second mineral acid in a second aqueous solution to give an eluted 223Ra solution; and iv) stripping the DGA separation medium of said 227Ac and 227Th by flowing a third mineral acid in a third aqueous solution through the DGA separation medium in a reversed direction; The invention further relates to high purity radium-223 formed or formable by such a method as well as pharmaceutical compositions comprising such radium-223 of pharmaceutical purity.